Latest Breaking News On - Movement disorder society sponsored revision - Page 1 : comparemela.com

GlobalData : Roche's PRX-002 shows promise in slowing Parkinson's disease motor progression, says GlobalData

19 Apr, 2024 Roche s PRX-002 shows promise in slowing Parkinson s disease motor progression, says GlobalData Share Print.

Clinical Study Demonstrates Viability of NeuraLight's Digital Biomarker Platform to Evaluate and Monitor Parkinson's Disease Progression

Data-driven algorithm predicts deep brain stimulation parameters for Parkinson's treatment

Researchers assesses the effects of stimulation parameters suggested by a recently published data-driven algorithm (StimFit) based on neuroimaging data.

Denali Therapeutics: Two Shots On Goal For Parkinson's Disease Treatment (NASDAQ:DNLI)

Denali Therapeutics is a great speculative biotech play to look into. This past year it has initiated two studies using a drug known as BIIB122. Click here to read more.

Annovis (ANVS): Late-Stage Parkinson's Disease Trial Advancement Makes It Worth A Look

Annovis is targeting large market indications and the two of them are Alzheimer's and Parkinson's. See why I believe that ANVS is a great speculative biotech play.